The research program will have two parts:~Stage 1: identification of patients with moderate, high and very high cardiovascular risk, not having diseases of atherosclerotic genesis and requiring lipid-lowering drugs.~Stage 2: a prospective observation of patients receiving primary medical prophylaxis of CVD with atorvastatin.
A systematic collection of retrospective and prospective data based on non-interventional patient observation, aimed to assess the risks, course and outcomes of a disease or a group of diseases:~the retrospective part: database of patients with cardiovascular risks;~the prospective part: observation of patients in the real world medical practice.